Joann Lin, MD
Allergy & Immunology · McKinney, TXNPI 1043232564
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,605 of the $13,705 with a category attached, or 84.7%. It is spread thinly across 42 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,317, 3.3 times the $997 reported in 2019.
Across 490 payments — averaging $27.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Regeneron Healthcare Solutions, Inc.$2K
- Genentech USA, Inc.$2K
- Takeda Pharmaceuticals U.S.A., Inc.$936
- GSK$794
- Sanofi$691
- plus $5K from 36 others
Across 18 payments — averaging $578.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- Shire North American Group Inc$4K
What the payments were for
- Consulting fees$1,90014%
- Food & beverage$11,60585%
- Education$2011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,705 in reported general payments places this provider in the 75th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 58 | $302,301 |
| TezspireTezepelumab-Ekko | 26 | $106,880 |
| Dupixent PenDupilumab | 23 | $84,149 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $54,271 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 14 | $51,480 |
| XolairOmalizumab | 13 | $49,630 |
| NucalaMepolizumab | 12 | $44,266 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $42,131 |
| Epinephrine | 66 | $13,666 |
| Spiriva RespimatTiotropium Bromide | 15 | $9,020 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $7,785 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $6,240 |
| Arnuity ElliptaFluticasone Furoate | 12 | $3,777 |
| DuleraMometasone/Formoterol | 11 | $3,195 |
| Ipratropium Bromide | 56 | $2,510 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $346 | $302,30158 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $2,916 | $155,25191 claims |
| GSKTrelegy Ellipta, Nucala, Arnuity Ellipta | $794 | $102,31486 claims |
| Grifols USA, LLCGamunex-C | $657 | $51,48014 claims |
| Hikma Pharmaceuticals USAEpinephrine | $62 | $13,66666 claims |
| Boehringer IngelheimSpiriva Respimat | $51 | $9,02015 claims |
| MerckDulera | $42 | $3,19511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in McKinney
- Joseph DiazSan Antonio$1.1M
- Richard WassermanDallas$452K
- Matthew FeldmanDallas$410K
- Lukena KarkhanisSan Antonio$377K
- Paul VigoAustin$304K
- Neha ReshamwalaAustin$303K
- Lara GrossDallas$171K
- Bobby LanierBenbrook$149K
- Juan ZambranoHouston$146K
- Serge de GolovineBellaire$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.